2023
Developing synthetic tools to decipher the tumor–immune interactome
Weizman O, Luyten S, Lu P, Song E, Qin K, Mostaghimi D, Ring A, Iwasaki A. Developing synthetic tools to decipher the tumor–immune interactome. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2306632120. PMID: 37871202, PMCID: PMC10622925, DOI: 10.1073/pnas.2306632120.Peer-Reviewed Original ResearchConceptsImmune cellsImmune-based therapiesTumor-immune cell interactionsDifferent immunotherapiesRetroviral reportersSensitive tumorsImmune surveillanceTumor subtypesTumor microenvironmentSynthetic Notch receptorCell interactionsCell contactTissue functionTissue locationNotch receptorsVivoOptimal tissue functionCellsComprehensive landscapeImmunotherapyTherapyTumorsImmunogenicitySubtypes
2019
Intratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses
Jiang X, Fedorova O, Linehan M, Dong H, Pyle A, Iwasaki A. Intratumoral delivery of RIG-I agonist induces robust anti-tumor immune responses. The Journal Of Immunology 2019, 202: 194.28-194.28. DOI: 10.4049/jimmunol.202.supp.194.28.Peer-Reviewed Original ResearchAnti-tumor efficacyRobust anti-tumor immune responseAnti-tumor immune responseTumor microenvironmentNucleic acid-sensing pathwaysT-cell depletionTumor-infiltrating lymphocytesCytosolic nucleic acid-sensing pathwaysB16 melanoma growthVivo anti-tumor efficacyPromising therapeutic agentLong-term survivalRemarkable antitumor effectImmunogenic tumorsInnate cellsCell depletionCancer immunotherapyMouse survivalImmune responseTumor volumeCombination treatmentIntratumoral deliveryAntitumor effectsMelanoma growthTumor subtypes